Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | ABL1 | P00519 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | STK17B | O94768 | 2/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15395957 | 0.89 | KMT2A (0.52) | ADORA3ABL1MEN1KMT2ASTK17B | |
| SCHEMBL23520278 | 0.77 | ADORA3 (0.65) | ADORA3ABL1MEN1KMT2AGSK3B | |
| SCHEMBL1916986 | 0.76 | KMT2A (0.70) | ADORA3MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL5550953 | 0.75 | IL2 (0.66) | ADORA3MEN1KMT2AKDM4E | |
| SCHEMBL5550933 | 0.75 | IL2 (0.56) | ADORA3MEN1KMT2AKDM4E | |
| SCHEMBL5550650 | 0.74 | ORAI1 (0.52) | ADORA3MEN1KMT2AKDM4E | |
| SCHEMBL8260166 | 0.74 | ALDH1A1 (0.47) | ADORA3MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL15395904 | 0.73 | ABL1 (0.52) | ABL1KMT2ANPSR1 | |
| SCHEMBL26154084 | 0.73 | KMT2A (0.69) | ADORA3MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL5550956 | 0.73 | ORAI1 (0.67) | ADORA3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101163478-B | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2013-11-27 | — | — | CN | claimed |
| CN-101163478-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2008-04-16 | — | — | CN | claimed |
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-9090570-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2015-07-28 | — | — | US | disclosed |
| CN-101163478-B | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2013-11-27 | — | — | CN | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| CN-101163478-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2008-04-16 | — | — | CN | disclosed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | ADORA3 548/4885ABL1 3979/4885MEN1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.